Search Results
Your search for The A matches 32956 pages
Showing 12551 - 12600Expert Point of View: Richard L. Schilsky, MD, FACP, FSCT, FASCO
Richard L. Schilsky, MD, FACP, FSCT, FASCO, Chief Medical Officer and Executive Vice President of ASCO, called the 74% response rate to cisplatin/gemcitabine “remarkable.” “What’s impressive to me is the high response rate, as well as the progression-free and overall survival data—these data are...
Cisplatin/Gemcitabine Alone and With Veliparib in BRCA-Mutated Advanced Pancreatic Cancer
In patients with pancreatic ductal adenocarcinoma and a germline BRCA/PALB2 mutation, first-line therapy with cisplatin plus gemcitabine yielded high response rates and encouraging survival, according to Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, who presented the findings...
Genetic Counseling and Testing of Patients With Pancreatic Cancer
Routine genetic counseling and multigene testing of patients with pancreatic cancer result in the detection of mutations that are actionable, not only for patients, but also for at-risk family members. At the Dana-Farber Cancer Institute in Boston, the use of a systemized, automated referral system ...
Maintenance Olaparib in BRCA1/2-Positive Pancreatic Cancer Yields Improved Progression-Free Survival, Preserves Quality of Life
Health-related quality of life was preserved during maintenance olaparib in patients with BRCA 1/2-positive pancreatic cancer, as evidenced by a low symptom burden over time.1 POLO investigators reported their findings in posters presented at the 2020 Gastrointestinal Cancers Symposium. Other...
Expert Point of View: Christopher M. Booth, MD
Christopher M. Booth, MD, the invited discussant of the BEACON CRC quality-of-life findings, applauded the investigators for choosing overall survival and quality of life as endpoints in a trial that benefits a “vulnerable patient population with unmet needs.” Patients with BRAF-mutated metastatic...
Mature Follow-up of BEACON CRC Study Reports Quality-of-Life Measures and Survival Outcomes
For patients with previously treated metastatic colorectal cancer harboring BRAF V600E mutations, the phase III BEACON CRC study showed the benefit for combining two or three targeted agents vs the standard of care.1 With further follow-up, the study has now also shown a benefit for the triplet and ...
TAPUR Basket Study: Biomarker-Driven Treatment Strategies Yield Benefits in Colorectal Cancer
Positive findings on the potential benefit of molecularly targeted drugs in patients with advanced colorectal cancer were presented at the 2020 Gastrointestinal Cancers Symposium, validating the purpose of ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) study.1-3 TAPUR, the first...
Expert Point of View: A. Craig Lockhart, MD
A. Craig Lockhart, MD, Professor of Medicine, University of Miami Sylvester Comprehensive Cancer Center, applauded the study for making patient-reported outcomes a prespecified endpoint and described the value of having this information. Dr. Lockhart was the invited discussant. “The U.S. Food and...
IMbrave150 Prespecified Analysis Adds Improved Quality-of-Life to Survival Benefits Reaped With Atezolizumab Plus Bevacizumab
New findings from a prespecified analysis of the pivotal IMbrave150 trial revealed improved quality of life for patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab in the first-line setting. These results were reported by Peter R. Galle, MD, at the 2020...
Conference Highlights From the 2020 Gastrointestinal Cancers Symposium
This past January, the 2020 Gastrointestinal Cancers Symposium was held in San Francisco. More than 3,600 individuals attended and more than 900 abstracts and posters were presented. Among the highlights presented at the meeting and reported in the pages of The ASCO Post, several studies in...
A Discussion About CAR T-Cell Therapy for Multiple Myeloma and Lymphoma
Dr. Armitage discusses the role of CAR T-cell therapy in the management of multiple myeloma and lymphoma in a conversation with his colleagues Dr. Holstein and Dr. Lunning.
A Case of Diffuse Large B-Cell Lymphoma
Dr. Armitage presents a case and asks Dr. Lunning to describe how he would treat this patient. The patient is a 52-year-old man who found a neck mass himself. He went to his doctor and was prescribed antibiotics. When the antibiotics failed to impact the mass, a biopsy was performed and a diagnosis ...
A Case of Relapsed/Refractory Multiple Myeloma
Dr. Armitage presents a case and asks Dr. Holstein to comment about her approach to treatment. The patient is be a 59-year-old man who had presented with symptomatic myeloma with bone pain and he was feeling unwell. He had bone lesions on images. He was anemic. This all happened 2 years ago. He was ...
A Case of Relapsed/Refractory Hodgkin Lymphoma
Dr. Armitage presents a case and asks Dr. Lunning to describe how he would treat this patient. The patient is a 25-year-old man with a diagnosis of stage III nodular sclerosing Hodgkin lymphoma. His disease went into complete remission when the patient was treated with ABVD and he was well. One...
A Case of Smoldering Myeloma
In this episode, Dr. Armitage presents a case and asks Dr. Holstein to comment on her approach to treatment of this individual. The patient is a 65-year-old man who was referred because of a monoclonal protein found in his blood. The patient was asymptomatic. He had a normal exam. He had an IgG...
Managing Cancer Care During the COVID-19 Pandemic
A special feature in JNCCN–Journal of the National Comprehensive Cancer Network by Ueda et al highlighted the unique circumstances and challenges of providing treatment to patients with cancer during the global COVID-19 pandemic. Physicians from the Seattle Cancer Care Alliance, Fred Hutchinson...
Expert Point of View: Charles G. Drake, MD, PhD
“This is a great study. It is one of the largest series of prostate-specific membrane antigen (PSMA) scans and covers many patient scenarios, including initial staging, restaging after surgery or radiation or hormonal therapy, and re-imaging in advanced disease,” said Charles G. Drake, MD, PhD, a...
PSMA PET/CT May Have Major Impact on Treatment of Patients With Prostate Cancer
Prostate cancer experts speaking at the 2020 Genitourinary Cancers Symposium alluded to the fact that prostate-specific membrane antigen (PSMA) positron-emission tomography (PET)/computed tomography (CT) scanning is more sensitive than conventional imaging for the detection of occult lesions in men ...
Trends in Deaths From Cutaneous Melanoma in the United States
Recent treatment advances in metastatic melanoma resulted in reductions in population-level mortality from the disease, according to a study published by Polsky et al in the American Journal of Public Health. Methods Researchers analyzed new cases and deaths from melanoma from nine U.S....
Association of Germline Variant Status and Response to Neoadjuvant Chemotherapy in High-Risk Early Breast Cancer
In a study of the GeparOcto trial population reported in JAMA Oncology, Pohl-Rescigno et al found that presence of germline BRCA1/2 variants was associated with increased rates of complete pathologic response (pCR) to neoadjuvant chemotherapy in women with high-risk early breast cancer, and that a...
Updated Analysis From KEYNOTE-189: Adding Pembrolizumab to Pemetrexed/Platinum for Nonsquamous NSCLC
An updated analysis from the phase III KEYNOTE-189 trial, reported by Shirish Gadgeel, MB, BS, and colleagues in the Journal of Clinical Oncology, indicated that the addition of pembrolizumab to pemetrexed/platinum chemotherapy continues to be associated with progression-free and overall survival...
Coronavirus, Patients With Cancer, and the Preparedness of the Institutions That Care for Them
We're covering the topic on everyone’s minds—coronavirus. We’ll start with the state of the epidemic as it relates to patients with cancer and the preparedness of the institutions that care for them. Next, we’ll look at a study from China that examined the impact of COVID-19 on patients with...
Digital Breast Tomosynthesis vs Digital Mammography Outcomes: Comparison Over 5 Years
A new study published by Conant et al in the journal Radiology found that the advantages of digital breast tomosynthesis over digital mammography, including increased cancer detection and fewer false-positive findings, are maintained over multiple years and rounds of screening. In addition,...
Surveillance for Second Malignant Neoplasms and Cardiac Dysfunction in Childhood Cancer Survivors
An analysis of the Childhood Cancer Survivor Study reported in the Journal of Clinical Oncology by Yan et al found that adherence to Children’s Oncology Group (COG) recommended surveillance for second malignant neoplasms and cardiac dysfunction in high-risk childhood cancer survivors is ...
Does Aspirin Use Lower the Risk of Hepatocellular Carcinoma and Liver-Related Mortality in Patients With Chronic Viral Hepatitis?
In a study reported in The New England of Medicine, Tracey G. Simon, MD, MPH, and colleagues found that low-dose aspirin use was associated with a reduced risk of hepatocellular carcinoma and liver-related mortality among patients with chronic hepatitis B or C infection. Study Details The study...
Reintroduction of FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
In the Italian phase III TRIBE2 trial reported in The Lancet Oncology, Cremolini et al found that reintroduction of FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab after progression on upfront treatment with the regimen was associated with improved...
COVID-19 May Remain Stable for Hours to Days in Aerosols and on Surfaces
The virus that causes coronavirus disease 2019 (COVID-19) is stable for several hours to days in aerosols and on surfaces, according to a new study published as a research letter in The New England Journal of Medicine. A team of researchers from the National Institutes of Health (NIH); the Centers ...
Cancer Incidence and Survivorship in Transgender Patients
The first-ever population-based study of cancer prevalence in transgender people was recently published by Boehmer et al in the journal Cancer. The authors of the report estimate that 62,530 of the nearly 17 million cancer survivors in the United States are transgender. Methods The researchers used ...
Spring 2020 ABIM Maintenance of Certification Exams Canceled
The American Board of Internal Medicine (ABIM) has announced that all spring 2020 maintenance of certification (MOC) assessment administrations are canceled in light of the COVID-19 pandemic. They issued the following communication: As frontline health-care professionals, many board-certified...
Proton Beam Therapy vs Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer
In a single-institution phase IIb trial reported in the Journal of Clinical Oncology, Steven H. Lin, MD, PhD, and colleagues found that proton beam therapy was associated with less toxicity and similar progression-free survival vs intensity-modulated radiation therapy in patients with locally...
Addition of Vincristine/Irinotecan to Established Chemotherapy Regimen in Patients With Diffuse Anaplastic Wilms Tumor
In a Children’s Oncology Group study (AREN0321) reported in the Journal of Clinical Oncology, Daw et al found that the addition of vincristine/irinotecan to a regimen used in the National Wilms Tumor Study 5 (NWTS-5; vincristine, doxorubicin, cyclophosphamide, carboplatin, and etoposide plus...
COVID-19 Infection in Patients With Cancer in China
In a study of the COVID-19 crisis in China reported in The Lancet Oncology, Liang et al found that patients with cancer may be at a higher risk of COVID-19 respiratory disease requiring admission to hospital than individuals without cancer, and that those with cancer who contract the virus have a...
Continuous Coverage of COVID-19
The staff of The ASCO Post recognizes the steady flow of news on the novel coronavirus, or COVID-19. Here, we've compiled a list of links to articles and resources on the COVID-19 pandemic. If you have a report you'd like to share, please e-mail it to us at editor@ascopost.com. Direct From ASCO:...
Strategies for Protecting Patients and Health-Care Providers Against COVID-19
For Patients Patients undergoing active treatment for cancer and cancer survivors may be at increased risk of becoming infected with the coronavirus because of their compromised immune system and their susceptibility to other illnesses. ASCO has developed information on Cancer.Net on how patients...
How COVID-19 Is Affecting the Oncology Community
Over the past month, medical societies worldwide have been monitoring the escalating outbreak of the novel coronavirus and its effect on international and domestic travel and making difficult decisions to cancel or postpone their scientific conferences or make them available digitally. On March...
Mitigating the Spread of COVID-19 and Its Impact on Cancer
On March 11, the World Health Organization (WHO) took the step it had been avoiding for weeks and declared that the spread of the coronavirus disease 2019 (COVID-19), and the virus that causes it, now identified as SARS-CoV-2, had reached global pandemic levels, the first pandemic sparked by a...
Selected Abstracts on Novel Treatments in Colon, Hepatocellular, and Biliary Tract Cancers
The ASCO Post has reported on the pivotal trials presented at the 2020 Gastrointestinal Cancers Symposium in several issues. Featured here are the findings of several additional abstracts worthy of mention. Intermittent Oxaliplatin in Stage II or III Colon Cancer As adjuvant treatment for stage II...
Are Younger Cancer Survivors More Susceptible to Financial and Food-Related Anxieties?
New research from the American Cancer Society published by Zheng et al in JNCCN–Journal of the National Comprehensive Cancer Network found that younger cancer survivors are more likely to experience significant financial strain for daily living necessities—such as food, housing, and monthly...
Risk of Cervical Cancer With Different Types of Intrauterine Devices
Patients who used copper intrauterine devices (IUDs) were found to have a lower risk of high-grade cervical neoplasms vs users of the levonorgestrel-releasing intrauterine system, according to a study published by Spotnitz et al in the journal Obstetrics & Gynecology. The study notes that more...
Adjuvant Etoposide/Cisplatin for Pathologic Stage II Nonseminomatous Germ Cell Tumors
In a single-center retrospective analysis reported by McHugh et al in the Journal of Clinical Oncology, two cycles of adjuvant etoposide plus cisplatin proved highly effective in patients with pathologic stage II nonseminomatous germ cell tumors. The combination also had acceptable toxicity and...
Neoadjuvant Cisplatin vs Doxorubicin/Cyclophosphamide for Patients With HER2-Negative Breast Cancer and a BRCA Mutation
In a phase II trial (INFORM; Translational Breast Cancer Research Consortium [TBCRC] 031) reported in the Journal of Clinical Oncology, Nadine Tung, MD, and colleagues found that neoadjuvant cisplatin did not improve pathologic complete response rate or residual cancer burden vs...
New ASCO Guideline Highlights the Management of Male Breast Cancer
THE ANNUAL INCIDENCE of male breast cancer in the United States is dwarfed by the rate among women. Yet, for the estimated 2,670 men who will be diagnosed with breast cancer this year, life-extending and life-enhancing treatments are crucial.1 To help reduce knowledge gaps and improve mortality and ...
Study Focuses on Role of Microbes in Pancreatic Cancer
Although bacteria are predominant in the gastrointestinal tract, they also reside on and in other parts of the body, including some unexpected places, such as malignant tumors. There are numerous reports of this phenomenon, but most have not identified a functional role for the microbes. In the...
FDA Pipeline: Breakthrough Therapy for NSCLC With Specific Mutation, Approval of Test for Cervical Cancer, and More
Over the past week, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to a bispecific antibody for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations; granted approval to a test for human...
Colorectal Cancer Statistics 2020 Published
The burden of colorectal cancer is shifting to younger individuals as incidence increases in young adults and declines in older age groups, according to Colorectal Cancer Statistics 2020. The median age of diagnosis dropped from 72 in 2001–2002 to 66 in 2015–2016. This finding and other data were...
Addition of Venetoclax to Cytarabine in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
In a phase I trial reported in The Lancet Oncology, Karol et al found that the combination of the BCL2 inhibitor venetoclax and the chemotherapeutic agent cytarabine with or without idarubicin produced responses in pediatric patients with relapsed or refractory acute myeloid leukemia. As noted by...
Evaluation of Genetic Testing in NCCN Criteria for Women With Breast Cancer
In a single-institution study reported in the Journal of Clinical Oncology, Yadav et al found that many women with breast cancer with germline pathogenic genetic variants do not qualify for genetic testing on current National Comprehensive Cancer Network® (NCCN®) hereditary testing criteria....
Conventionally Fractionated vs Moderate Hypofractionated Radiation Therapy for Localized Prostate Cancer: Long-Term Update
As reported in the Journal of Clinical Oncology by Avkshtol et al, the 10-year update of a single-center trial has confirmed the primary analysis of the study, showing no superiority in 5-year biochemical and/or clinical disease failure rate with moderate hypofractionated intensity-modulated...
Pembrolizumab Plus Radiotherapy Worthy of Further Study in Locally Advanced Squamous Cell Head and Neck Cancer
The combination of the checkpoint inhibitor pembrolizumab and definitive radiation therapy appears to be a safe and feasible option for patients with locally advanced head and neck cancer who are not eligible for cisplatin, according to data presented at the 2020 Multidisciplinary Head and Neck...
Annual Report to the Nation on the Status of Cancer Released
The Annual Report to the Nation on the Status of Cancer has found that cancer death rates continued to decline from 2001 to 2017 in the United States for all cancer sites combined. The report was published by Hensley et al in the journal Cancer. The annual report is a collaborative effort among the ...
